A survival prognostic model for gastro-intestinal diffuse large B-cell lymphomas: A multicenter retrospective study

Area of Science:

• Oncology
• Hematology
• Clinical Research

Background:

• Primary gastro-intestinal lymphomas (PGIL) are the most common extra-nodal lymphomas.
• Existing prognostic models for gastrointestinal diffuse large B-cell lymphoma (GI-DLBCL) require rigorous external validation.

Purpose of the Study:

• To establish and validate a robust prognostic model for primary gastro-intestinal diffuse large B-cell lymphoma (PGI-DLBCL).
• To identify key prognostic factors for survival in PGI-DLBCL patients treated with R-CHOP.

Main Methods:

• A multi-center retrospective study involving 1,023 PGIL patients from 9 Chinese medical centers.
• A training cohort of 462 PGI-DLBCL patients treated with R-CHOP and an external validation cohort of 192 PGI-DLBCL patients.
• Development of a survival prognosis nomogram model based on multivariate analysis.

Main Results:

• Patients receiving R-CHOP demonstrated significantly better survival than those receiving CHOP alone (P<0.001).
• Significant independent prognostic factors identified in the training cohort were Age (P=0.03), Lugano stage (P<0.001), Hemoglobin (P=0.04), and Lactic dehydrogenase (LDH) (P<0.001).
• The developed nomogram model achieved high predictive accuracy with C-statistics of 0.83 in the training cohort and 0.81 in the validation cohort.

Conclusions:

• The novel 4-variable nomogram model (Age, Lugano stage, LDH, Hemoglobin) is effective for predicting survival in PGI-DLBCL patients.
• This validated model offers a valuable tool for clinical decision-making and patient management in PGI-DLBCL.